NEW BRUNSWICK, N.J., Sept. 18, 2012 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 16th, to review third-quarter results. Dominic Caruso, Vice President, Finance and Chief Financial Officer, Paul Stoffels, M.D., Chief Scientific Officer (effective Oct.1), and Worldwide Chairman, Pharmaceuticals, Joaquin Duato, Worldwide Chairman, Pharmaceuticals, and Louise Mehrotra, Vice President, Investor Relations, will host the call.
Investors and other interested parties may access the conference call in the following ways:
- At Johnson & Johnson's website: www.investor.jnj.com. This earnings webcast is optimized for mobile streaming on iOS devices such as iPhones, iPods, and iPads. A webcast and podcast replay will be available approximately two hours after the conference call concludes.
- By telephone: For both "listen-only" participants and those financial analysts who wish to take part in the question-and-answer portion of the call, the telephone dial-in number in the U.S. is 877-616-4355. For participants outside the U.S., the dial-in number is 706-758-9071. The conference ID number for all callers is 30006671. A replay of the conference call will be available beginning at approximately 11:30 a.m. on October 16, 2012, and ending at approximately 12:00 a.m. on October 23, 2012. The replay dial-in number for U.S. participants is 855-859-2056. For participants outside the U.S., the replay dial-in number is 404-537-3406. The replay conference ID number for all callers is 30006671.
About Johnson & Johnson
Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 128,000 employees at more than 250 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.
SOURCE Johnson & Johnson